CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 21 enrolled
Drug / intervention
vaginal estrioldrug
Likely dose
vaginal estriol 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03774407
NCT03774407Phase 3Completed
CompareCT.gov

Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS)

Texas Tech University Health Sciences Center·interventional·Posted Dec 13, 2018·Updated Sep 21, 2022

In Brief

A Phase 3 clinical trial evaluating vaginal estriol for Multiple Sclerosis and Neurogenic Bladder. Completed, enrolled 21 participants across 1 site.

Detailed Summary

Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Neurogenic Bladder
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedDec 13, 2018
Enrollment StartJun 20, 2019
Primary CompletionNov 10, 2020
Study CompletionNov 29, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.6 years ago

Interventions

vaginal estrioldrug

Estriol vaginal cream will be formulated by Twin Oaks specialty pharmacy-by the same compound specialist. 30 mg estriol powder will be mixed with 5 mL of propylene glycol and 22 g of vaginal base cream. The product can be stored at room temperature and has a shelf life of up to 4 months. It comes with an applicator.